PMID- 15725079
OWN - NLM
STAT- MEDLINE
DCOM- 20050412
LR  - 20050223
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 128
IP  - 5
DP  - 2005 Mar
TI  - Low molecular weight heparin in pregnancy: current issues.
PG  - 593-601
AB  - Low molecular weight heparin (LMWH) is now the most commonly used anticoagulant 
      for prophylaxis and treatment of venous thromboembolism in pregnancy and the 
      puerperium in the UK. The reliable pharmacokinetics of LMWHs and their long 
      half-life, resulting in the need for less frequent injections than unfractionated 
      heparin (UFH), makes them attractive for practical use in the 9 months of 
      pregnancy. Widespread use over the last 10 years has shown that LMWHs are safer 
      than UFH in pregnancy. There is, however, poor consensus and wide disparity of 
      views among experts with regard to the appropriate dose for the varying 
      indications, the duration of treatment, and whether and how LMWH should be 
      monitored because of the lack of an evidence base. These areas of uncertainty 
      reflect the fact that clinical practice has grown largely through the publication 
      of small trials, observational studies, personal experience and anecdote. Good 
      clinical trials are urgently required.
FAU - Greer, Ian
AU  - Greer I
AD  - Division of Developmental Medicine, University of Glasgow, Glasgow Royal 
      Infirmary, Scotland.
FAU - Hunt, Beverley J
AU  - Hunt BJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Drug Administration Schedule
MH  - Female
MH  - Heart Valve Prosthesis
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Placenta Diseases/prevention & control
MH  - Pregnancy
MH  - Pregnancy Complications, Hematologic/*drug therapy/prevention & control
MH  - Thromboembolism/*drug therapy/prevention & control
MH  - Treatment Outcome
RF  - 92
EDAT- 2005/02/24 09:00
MHDA- 2005/04/13 09:00
CRDT- 2005/02/24 09:00
PHST- 2005/02/24 09:00 [pubmed]
PHST- 2005/04/13 09:00 [medline]
PHST- 2005/02/24 09:00 [entrez]
AID - BJH5304 [pii]
AID - 10.1111/j.1365-2141.2004.05304.x [doi]
PST - ppublish
SO  - Br J Haematol. 2005 Mar;128(5):593-601. doi: 10.1111/j.1365-2141.2004.05304.x.